1987. One-Year Mortality and Reoperation Among Patients with Infective Endocarditis After Transcatheter or Surgical Aortic Valve Replacement


 
 
 Treatment of severe aortic valve stenosis with transcatheter aortic valve implantation (TAVI) was initially developed for older patients at high surgical risk. However, with improving technology and experience, indications for TAVI have expanded to include younger patients and those at moderate surgical risk, leading to increasing use of TAVI as an alternative to surgical aortic valve replacement (SAVR). As a result, post-TAVI infective endocarditis (IE) is increasingly common. Data on post-TAVI IE in comparison to post-SAVR IE outcomes are limited.
 
 
 
 Using data from the TriNetX Research Network, we identified (1) a cohort of patients who underwent TAVI between 1/1/2016 and 12/31/2020 (CPT procedure code 1021150) and developed IE (captured with ICD-10 codes I33, I38, or I39) after the procedure; and (2) a propensity score-matched cohort of patients who underwent SAVR (CPT procedure codes 1006141, excluding any associated transcatheter procedures) and developed IE. Both cohorts were required to have at least 1 week follow-up, i.e., deaths within 7 days of IE were excluded. We matched the cohorts for demographics and clinically relevant background characteristics. We used Kaplan-Meier estimates for 1-year mortality and aortic valve reoperation and Cox proportional hazards models to compare event rates.
 
 
 
 We identified 616 patients with post-TAVI IE and 616 matched patients with post-SAVR IE. The baseline characteristics of the cohorts were well balanced, as indicated by standardized mean differences < 0.1, Table 1. The Kaplan-Meier 1-year mortality between 7 days and 1 year (as deaths before 7 days were excluded) was 20.9% in the TAVI cohort (117 events) vs. 13.0% in the SAVR cohort (72 events), HR 1.66 (95%CI 1.24-2.22; P=0.001), Figure 1. Reoperation for the aortic valve by 1 year was uncommon in both groups, with 12 and 10 events in the TAVI and SAVR groups, respectively (2.0% vs. 1.4%; HR 1.49, 95%CI 0.61-3.65; P=0.56).
 Baseline Patient Characteristics After Matching
 Figure 1
 One-year survival post infective endocarditis after transcatheter aortic valve implantation (TAVI IE) or surgical aortic valve replacement (SAVR IE). Deaths within 7 days of infective endocarditis diagnosis were excluded.
 
 
 
 In this comparative, propensity-matched cohort study, 1-year mortality after an episode of IE was significantly higher among TAVI recipients vs their SAVR counterparts. Repeat aortic valve procedures were uncommon in both groups. Prospective studies are needed to elucidate the causes of excess mortality among TAVI recipients.
 
 
 
 All Authors: No reported disclosures.
